LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Search

CytoSorbents Corp

Fechado

SetorSaúde

0.65 -10.96

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.65

Máximo

0.73

Indicadores-chave

By Trading Economics

Rendimento

-5.1M

-3.2M

Vendas

-132K

9.5M

EPS

-0.05

Margem de lucro

-33.421

Funcionários

149

EBITDA

-5.9M

-2.9M

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

156K

45M

Abertura anterior

11.61

Fecho anterior

0.65

Sentimento de Notícias

By Acuity

100%

0%

362 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de dez. de 2025, 22:02 UTC

Ganhos

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 de dez. de 2025, 21:46 UTC

Ganhos

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 de dez. de 2025, 23:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 de dez. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 de dez. de 2025, 23:36 UTC

Conversa de Mercado

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 de dez. de 2025, 23:20 UTC

Ganhos

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 de dez. de 2025, 23:15 UTC

Ganhos

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 de dez. de 2025, 22:59 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 de dez. de 2025, 22:45 UTC

Conversa de Mercado

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 de dez. de 2025, 22:40 UTC

Ganhos

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 de dez. de 2025, 22:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 de dez. de 2025, 22:06 UTC

Ganhos

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 de dez. de 2025, 22:02 UTC

Ganhos

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 de dez. de 2025, 22:00 UTC

Ganhos

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 de dez. de 2025, 21:53 UTC

Ganhos

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 de dez. de 2025, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 de dez. de 2025, 21:50 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

10 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

10 de dez. de 2025, 21:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 de dez. de 2025, 21:33 UTC

Ganhos

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 de dez. de 2025, 21:32 UTC

Ganhos

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 de dez. de 2025, 21:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 de dez. de 2025, 21:25 UTC

Ganhos

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 de dez. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 de dez. de 2025, 21:16 UTC

Ganhos

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 de dez. de 2025, 21:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 de dez. de 2025, 21:15 UTC

Ganhos

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 de dez. de 2025, 21:14 UTC

Ganhos

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 de dez. de 2025, 21:14 UTC

Ganhos

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.705 / 0.771Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

362 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
help-icon Live chat